Three independent discounted-cash-flow-style models value Krystal Biotech, Inc. every trading day. 0 of 3 currently price KRYS above its market price.
| Free Cash Flow model | $-205.81 |
| Excess Profit model | $-130.51 |
| Residual Earnings model | $-4.09 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +10.4% |
| Net debt / EBITDA | -2.9× |
| Gross margin | +94.1% |
| Revenue CAGR | — |
| Cash conversion | 1.0× |
| Dividend yield | — |
| Buyback yield | -1.4% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open KRYS in StockKitty